Literature DB >> 9307268

Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo.

C S Chiang1, R G Syljuäsen, J H Hong, A Wallis, G J Dougherty, W H McBride.   

Abstract

Expression of a murine interleukin 3 gene in murine fibrosarcoma cells (FSA-JmIL-3) did not alter their survival after in vitro irradiation. However, FSA-JmIL-3 tumors established in vivo were much more sensitive to irradiation than was the parental tumor. Following 25 Gy of irradiation, parental fibrosarcoma tumors regrew after a growth delay of 10 days, but FSA-JmIL-3 tumors continued to regress. Examination of the cellular composition of tumors following irradiation revealed that, instead of tumor cell repopulation, the FSA-JmIL-3 tumors became heavily infiltrated with lymphocytes, indicating that the effect of irradiation was to allow the IL-3-elicited cellular immune response to infiltrate the tumors and mediate rejection. This study indicates that combining gene immunotherapy approaches with radiotherapy might increase the effectiveness of both, and it seems logical to pursue such treatment options.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307268

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Combining radiotherapy and immunotherapy: a revived partnership.

Authors:  Sandra Demaria; Nina Bhardwaj; William H McBride; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

2.  Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.

Authors:  Timothy J Harris; Edward L Hipkiss; Scott Borzillary; Satoshi Wada; Joseph F Grosso; Hung-Rong Yen; Derese Getnet; Tullia C Bruno; Monica V Goldberg; Drew M Pardoll; Theodore L DeWeese; Charles G Drake
Journal:  Prostate       Date:  2008-09-01       Impact factor: 4.104

3.  Local irradiation of murine melanoma affects the development of tumour-specific immunity.

Authors:  Yu-Pei Liao; Chun-Chieh Wang; Dörthe Schaue; Keisuke S Iwamoto; William H McBride
Journal:  Immunology       Date:  2009-02-17       Impact factor: 7.397

4.  Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors.

Authors:  Chao-Yi Wu; Li-Hua Yang; Huang-Yu Yang; Jayne Knoff; Shiwen Peng; Yi-Hsin Lin; Chenguang Wang; Ronald D Alvarez; Sara I Pai; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Clin Cancer Res       Date:  2013-12-03       Impact factor: 12.531

5.  Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4+ effector T cell infiltration into murine pancreatic tumors.

Authors:  Neeha Zaidi; Sergio A Quezada; Janelle M Y Kuroiwa; Li Zhang; Elizabeth M Jaffee; Ralph M Steinman; Bei Wang
Journal:  Ann N Y Acad Sci       Date:  2019-04-04       Impact factor: 6.499

6.  Alteration of tumour response to radiation by interleukin-2 gene transfer.

Authors:  J Lee; J P Moran; B M Fenton; C J Koch; J G Frelinger; P C Keng; E M Lord
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

Review 7.  Tumor associated macrophage: a review on the phenotypes, traits and functions.

Authors:  Suhashini Ramanathan; Nithya Jagannathan
Journal:  Iran J Cancer Prev       Date:  2014

8.  Extremely low-frequency electromagnetic fields cause G1 phase arrest through the activation of the ATM-Chk2-p21 pathway.

Authors:  Chao-Ying Huang; Cheng-Wei Chang; Chaang-Ray Chen; Chun-Yu Chuang; Chi-Shiun Chiang; Wun-Yi Shu; Tai-Ching Fan; Ian C Hsu
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

9.  Selected anti-tumor vaccines merit a place in multimodal tumor therapies.

Authors:  Eva-Maria Weiss; Roland Wunderlich; Nina Ebel; Yvonne Rubner; Eberhard Schlücker; Roland Meyer-Pittroff; Oliver J Ott; Rainer Fietkau; Udo S Gaipl; Benjamin Frey
Journal:  Front Oncol       Date:  2012-10-09       Impact factor: 6.244

10.  The roles of macrophages and nitric oxide in interleukin-3-enhanced HSV-Sr39tk-mediated prodrug therapy.

Authors:  Ching-Fang Yu; Ji-Hong Hong; Chi-Shiun Chiang
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.